CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care
Key Highlights
- ➤CytoSorbents (CTSO) announces data presentations at EACTS and ESICM conferences
- ➤Four cardiac surgery presentations will feature CytoSorb data at EACTS 2026
- ➤COSMOS Registry data will cover liver support, ECMO, vasoplegia, and septic shock
- ➤CytoSorb (CTSO) has more than 300,000 devices used cumulatively to date
- ➤CytoSorbents (CTSO) pursuing U.S. FDA and Health Canada approval for DrugSorb-ATR
Expert Statements
Phillip Chan, Chief Executive Officer of CytoSorbents
“We are pleased to see such a broad body of clinical data on CytoSorb accepted for presentation at two of the world's leading cardiac surgery and critical care conferences.”
Phillip Chan, Chief Executive Officer of CytoSorbents
“These presentations span important areas of unmet medical need across cardiac surgery - including the removal of blood thinners, heart transplantation, heart failure, and shock following open heart surgery - as well as critical care applications such as acute liver disease, acute respiratory distress syndrome (ARDS), and septic shock.”
Phillip Chan, Chief Executive Officer of CytoSorbents
“The latter is particularly timely as Sepsis Awareness Month draws to a close and reinforces the continued need for more powerful approaches like CytoSorb to help manage the life-threatening hyperinflammation and organ dysfunction associated with this devastating condition.”
Phillip Chan, Chief Executive Officer of CytoSorbents
“We remain deeply committed to supporting high-quality clinical research and expanding the evidence base for CytoSorb across a wide range of deadly conditions.”
Phillip Chan, Chief Executive Officer of CytoSorbents
“A cornerstone of this effort is our international, prospective, multicenter COSMOS Registry, which is designed to systematically capture real-world clinical experience with CytoSorb across a broad spectrum of critically ill patients.”
Phillip Chan, Chief Executive Officer of CytoSorbents
“By generating data on how CytoSorb is being used in everyday clinical practice - including patient selection, timing and duration of therapy, safety, and clinical outcomes - COSMOS is providing important insights that complement controlled clinical studies, help clinicians further refine and optimize CytoSorb therapy, and help to further establish the role of CytoSorb in the management of complex cardiac surgery and critical care patients worldwide.”
Phillip Chan, Chief Executive Officer of CytoSorbents
“We are excited to see this growing body of evidence being shared with the international medical community.”
CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care PR Newswire
PRINCETON, N.J., Sept. 30, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces upcoming data presentations using CytoSorb® in open heart surgery at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Barcelona, Spain from October 7-10, 2026 and in critical care at the European Society of Intensive Care Medicine (ESICM) Annual Congress in Lisbon, Portugal from October 10-14, 2026.
Get started
Create a free account to read the full story.